Gallium nitrate
13494-90-1O=[N+]([O-])[O-].O=[N+]([O-])[O-].O=[N+]([O-])[O-].[Ga+3]CHPZKNULDCNCBW-UHFFFAOYSA-NGallium nitrate appears as white crystals. (NTP, 1992)
13494-90-1DTXSID0043923CHEMBL1200983CHEBI:231505FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Danger
H272 (100%): May intensify fire; oxidizer [Danger Oxidizing liquids; Oxidizing solids]
P210, P220, P260, P261, P264, P264+P265, P271, P280, P301+P330+P331, P302+P352, P302+P361+P354, P304+P340, P305+P351+P338, P305+P354+P338, P316, P319, P321, P332+P317, P337+P317, P362+P364, P363, P370+P378, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 10 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Oxidizing agents, such as GALLIUM NITRATE, can react with reducing agents to generate heat and products that may be gaseous (causing pressurization of closed containers). The products may themselves be capable of further reactions (such as combustion in the air). The chemical reduction of materials in this group can be rapid or even explosive, but often requires initiation (heat, spark, catalyst, addition of a solvent). Explosive mixtures of inorganic oxidizing agents with reducing agents often persist unchanged for long periods if initiation is prevented. Such systems are typically mixtures of solids, but may involve any combination of physical states. Some inorganic oxidizing agents are salts of metals that are soluble in water; dissolution dilutes but does not nullify the oxidizing power of such materials. Organic compounds, in general, have some reducing power and can in principle react with compounds in this class. Actual reactivity varies greatly with the identity of the organic compound. Inorganic oxidizing agents can react violently with active metals, cyanides, esters, and thiocyanates.
Gallium nitrate produces a hypocalcemic effect by inhibiting calcium resorption from bone, possibly blocking osteoclast activity and reducing increased bone turnover. Preclinical studies demonstrated that gallium dose-dependently accumulates in areas of high bone turnover, where it is incorporated into hydroxyapatite, making it less susceptible to dissolution and osteoclast-mediated resorption. No cytotoxic effects were observed on bone cells in drug-treated animals. Gallium nitrate exhibits antitumour activity, which is reported to be unrelated to the physiological mechanism involved in its bone turnover effects. Anti-inflammatory and immunosuppressant effects have also been documented.
A high incidence of hypercalcemia is often observed in patients with non-small cell lung cancer, breast cancer, multiple myeloma, kidney cancer, and cancer of head and neck. Hypercalcemia of malignancy seems to result from an imbalance between the net resorption of bone and urinary excretion of calcium. Patients with extensive osteolytic bone metastases frequently develop hypercalcemia. Although _in vitro_ and animal studies have been performed to investigate the mechanism of action of gallium nitrate, the precise mechanism for inhibiting calcium resorption has not been determined. Gallium, the active component that exerts the physiological effects of gallium nitrate, may induce physicochemical changes in the bone matrix to promote hydroxyapatite crystallization and attenuate mineral dissolution. Gallium may also decrease acid secretion by osteoclasts and modulate the synthesis of osteocalcin, an osteoblast-specific bone matrix protein that triggers bone resorption. Osteoclast morphology or viability is not reported to be affected. Gallium nitrate may modulate inflammation. _In vitro_, it was shown to block the production of inflammatory cytokines, such as interleukin-1 (IL-1) beta, by macrophage-like cells. Gallium nitrate also dose-dependently inhibited matrix metalloproteinase activity promoted by tissue plasminogen activator (tPA).
In phase I studies involving cancer patients who received a short-term intravenous infusion of single doses ranging from 300 to 900 mg/m<sup>2</sup>, a biphasic curve was observed. Gallium nitrate exhibited a mean initial (distribution phase) half-life of 1 to 1.5 hours and a terminal (elimination phase) half-lives of 25 to 30 hours.
EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.
SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.
RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)
Drug Induced Liver Injury Rank (DILIrank 2.0)
Gallium nitrate
Ambiguous-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Y2V2R4W9TQ
GALLIUM NITRATE ANHYDROUS
Physiologic Effects [PE] - Bone Resorption Inhibition
Established Pharmacologic Class [EPC] - Calcium Resorption Inhibitor
Gallium nitrate anhydrous is a Calcium Resorption Inhibitor. The physiologic effect of gallium nitrate anhydrous is by means of Bone Resorption Inhibition.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Hormones and molecules with calcium-regulating hormone-like actions that modulate OSTEOLYSIS and other extra-skeletal activities to maintain calcium homeostasis.
Gallium nitrate was infused at a daily dose of 200 mg/m2 for 5 (n=2) or 7 (n=10) consecutive days to 12 cancer patients. In most patients, mean steady-state plasma concentrations were reached after 18 to 24 hours of infusion. The average steady-state plasma levels of gallium observed among seven fully evaluable patients was between 1134 and 2399 ng/mL. In one patient who received daily infusion doses of 100, 150 and 200 mg/m2, the apparent steady-state levels of gallium did not increase proportionally with an increase in dose.
Gallium nitrate appears to be significantly excreted via the kidney. In phase I studies involving cancer patients who received a short-term intravenous infusion of single doses ranging from 300 to 900 mg/m<sup>2</sup>, about two-thirds of the administered dose was recovered in the urine in the first 24 hours post-dose.
In phase I studies involving cancer patients who received a short-term intravenous infusion of single doses ranging from 300 to 900 mg/m<sup>2</sup>, the mean volume of distribution of gallium was 1.27 L/kg.
In cancer patients who received a daily infusion of gallium nitrate at a dose of 200 mg/m<sup>2</sup> for five to seven consecutive days, the average plasma clearance of gallium was 0.15 L/hr/kg (range: 0.12 to 0.20 L/hr/kg).
BeschreibungGallium nitrate, initially developed as an anticancer agent, was introduced by Fujisawa as an orphan drug for the treatment of cancer-related hypercalcemia and bone metastases that do not respond to adequate hydration. The compound acts specifically on bone by inhibiting calcium resorption and also possibly by stimulating bone formation. Compared with calcitonin and etidronate, gallium nitrate is more potent and substantially longer acting. Other potential uses could be in the treatment of osteoporosis and Paget’s disease.
VerwendenGallium is the second metal ion with clinical activity used in cancer treatment. Gallium nitrate has demonstrated antitumor activity in a variety of murine tumor models, including Walker 256 carcinosarcoma, fibrosarcoma M-89, leukemia K-1964, adenocarcinoma 755, mammary carcinoma YMC, reticulum cell sarcoma A-RCS, lymphoma P1798, and osteosarcoma 124F. It was, however, ineffective in ascites, leukemias, plasma cell tumors, or Ehrlich carcinoma. In phase II evaluation studies, gallium nitrate has shown antitumor activity in patients with either refractory lymphomas or small-cell lung carcinomas or bladder cancer, with total objective response rates of 28% and 11%, respectively. This drug has displayed its strongest antineoplastic activity in the treatment of non-Hodgkin’s lymphoma and bladder cancer. In addition, according to two phase III comparative trials,thanks to an inhibitory effect on calcium reabsorption from bone, gallium nitrate is superior to alternative therapies in the treatment of hypercalcemia associated with malignancy and related disease states. Based on its clinical efficacy, gallium nitrate (Ganite ) was approved by the Food and Drug Administration (FDA) for the treatment of cancerassociated hypercalcemia.Apart from its ability to control hypercalcemia, gallium nitrate has been shown to inhibit bone turnover and decrease osteolysis in patients with multiple myeloma and in patients with bone metastases from a variety of different cancers.